• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

可溶性人 LOX-1 产生的裂解位点的模拟和实验研究。

Simulative and experimental investigation on the cleavage site that generates the soluble human LOX-1.

机构信息

Department of Systems Medicine, University of Rome "Tor Vergata", Via Montpellier 1, 00133 Rome, Italy.

出版信息

Arch Biochem Biophys. 2013 Dec;540(1-2):9-18. doi: 10.1016/j.abb.2013.10.001. Epub 2013 Oct 7.

DOI:10.1016/j.abb.2013.10.001
PMID:24113299
Abstract

Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is a scavenger receptor that mediates the recognition, the binding and internalization of ox-LDL. A truncated soluble form of LOX-1 (sLOX-1) has been identified that, at elevated levels, has been associated to acute coronary syndrome. Human sLOX-1 is the extracellular part of membrane LOX-1 which is cleaved in the NECK domain with a mechanism that has not yet been identified. Purification of human sLOX-1 has been carried out to experimentally identify the cleavage site region within the NECK domain. Molecular modelling and classical molecular dynamics simulation techniques have been used to characterize the structural and dynamical properties of the LOX-1 NECK domain in the presence and absence of the CTLD recognition region, taking into account the obtained proteolysis results. The simulative data indicate that the NECK domain is stabilized by the coiled-coil heptad repeat motif along the simulations, shows a definite flexibility pattern and is characterized by specific electrostatic potentials. The detection of a mobile inter-helix space suggests an explanation for the in vivo susceptibility of the NECK domain to the proteolytic cleavage, validating the assumption that the NECK domain sequence is composed of a coiled-coil motif destabilized in specific regions of functional significance.

摘要

凝集素样氧化型低密度脂蛋白受体-1(LOX-1)是一种清道夫受体,介导对氧化型 LDL 的识别、结合和内化。已经鉴定出 LOX-1 的一种截断可溶性形式(sLOX-1),其在升高的水平与急性冠状动脉综合征相关。人 sLOX-1 是人膜 LOX-1 的细胞外部分,其在 NECK 结构域中通过尚未确定的机制被切割。已经进行了人 sLOX-1 的纯化,以实验鉴定 NECK 结构域中的切割位点区域。已经使用分子建模和经典分子动力学模拟技术来表征 LOX-1 NECK 结构域在存在和不存在 CTLD 识别区域时的结构和动力学特性,同时考虑到获得的蛋白水解结果。模拟数据表明,NECK 结构域在整个模拟过程中沿着卷曲螺旋七肽重复基序稳定,表现出明确的柔韧性模式,并具有特定的静电势。检测到一个可移动的螺旋间空间,这为 NECK 结构域在体内易受蛋白水解切割的原因提供了一个解释,验证了这样的假设,即 NECK 结构域序列由在功能重要的特定区域不稳定的卷曲螺旋基序组成。

相似文献

1
Simulative and experimental investigation on the cleavage site that generates the soluble human LOX-1.可溶性人 LOX-1 产生的裂解位点的模拟和实验研究。
Arch Biochem Biophys. 2013 Dec;540(1-2):9-18. doi: 10.1016/j.abb.2013.10.001. Epub 2013 Oct 7.
2
Chimeric structural stabilities in the coiled-coil structure of the NECK domain in human lectin-like oxidized low-density lipoprotein receptor 1 (LOX-1).人凝集素样氧化型低密度脂蛋白受体1(LOX-1)颈部结构域卷曲螺旋结构中的嵌合结构稳定性。
J Biochem. 2007 Jun;141(6):855-66. doi: 10.1093/jb/mvm093. Epub 2007 Apr 6.
3
Molecular mechanism of statin-mediated LOX-1 inhibition.他汀类药物介导的凝集素样氧化低密度脂蛋白受体-1(LOX-1)抑制的分子机制。
Cell Cycle. 2015;14(10):1583-95. doi: 10.1080/15384101.2015.1026486.
4
Lectin-like oxidized low-density lipoprotein receptor 1 signal is a potent biomarker and therapeutic target for human rheumatoid arthritis.凝集素样氧化型低密度脂蛋白受体1信号是人类类风湿关节炎的一种有效生物标志物和治疗靶点。
Arthritis Rheum. 2012 Apr;64(4):1024-34. doi: 10.1002/art.33452. Epub 2011 Nov 10.
5
Essential role of cytoplasmic sequences for cell-surface sorting of the lectin-like oxidized LDL receptor-1 (LOX-1).细胞质序列在凝集素样氧化型低密度脂蛋白受体1(LOX-1)细胞表面分选过程中的重要作用。
J Mol Cell Cardiol. 2005 Sep;39(3):553-61. doi: 10.1016/j.yjmcc.2005.05.001.
6
Surface plasmon resonance study on functional significance of clustered organization of lectin-like oxidized LDL receptor (LOX-1).凝集素样氧化型低密度脂蛋白受体(LOX-1)簇状组织功能意义的表面等离子体共振研究
Biochim Biophys Acta. 2011 Feb;1814(2):345-54. doi: 10.1016/j.bbapap.2010.10.006. Epub 2010 Oct 28.
7
Crystal structure of human lectin-like, oxidized low-density lipoprotein receptor 1 ligand binding domain and its ligand recognition mode to OxLDL.人凝集素样氧化型低密度脂蛋白受体1配体结合域的晶体结构及其对氧化型低密度脂蛋白的配体识别模式
Structure. 2005 Jun;13(6):905-17. doi: 10.1016/j.str.2005.03.016.
8
Structural implication for the impaired binding of W150A mutant LOX-1 to oxidized low density lipoprotein, OxLDL.W150A突变型凝集素样氧化低密度脂蛋白受体1(LOX-1)与氧化型低密度脂蛋白(OxLDL)结合受损的结构影响
Biochim Biophys Acta. 2012 May;1824(5):739-49. doi: 10.1016/j.bbapap.2012.02.003. Epub 2012 Feb 18.
9
Design of a novel LOX-1 receptor antagonist mimicking the natural substrate.新型 LOX-1 受体拮抗剂的设计模拟天然底物。
Biochem Biophys Res Commun. 2013 Aug 23;438(2):340-5. doi: 10.1016/j.bbrc.2013.07.073. Epub 2013 Jul 26.
10
The splice variant LOXIN inhibits LOX-1 receptor function through hetero-oligomerization.剪接变体LOXIN通过异源寡聚化抑制LOX-1受体功能。
J Mol Cell Cardiol. 2008 Mar;44(3):561-70. doi: 10.1016/j.yjmcc.2007.11.017. Epub 2007 Dec 7.

引用本文的文献

1
Novel cardiac biomarkers and multiple-marker approach in the early detection, prognosis, and risk stratification of cardiac diseases.新型心脏生物标志物及多标志物方法在心脏病早期检测、预后评估及风险分层中的应用
World J Cardiol. 2025 Jul 26;17(7):106561. doi: 10.4330/wjc.v17.i7.106561.
2
Radical Oxygen Species, Oxidized Low-Density Lipoproteins, and Lectin-like Oxidized Low-Density Lipoprotein Receptor 1: A Vicious Circle in Atherosclerotic Process.活性氧、氧化型低密度脂蛋白和凝集素样氧化型低密度脂蛋白受体1:动脉粥样硬化进程中的恶性循环。
Antioxidants (Basel). 2024 May 9;13(5):583. doi: 10.3390/antiox13050583.
3
Proteolytic Regulation of the Lectin-Like Oxidized Lipoprotein Receptor LOX-1.
凝集素样氧化脂蛋白受体LOX-1的蛋白水解调控
Front Cardiovasc Med. 2021 Jan 20;7:594441. doi: 10.3389/fcvm.2020.594441. eCollection 2020.
4
Role of LOX-1 (Lectin-Like Oxidized Low-Density Lipoprotein Receptor 1) as a Cardiovascular Risk Predictor: Mechanistic Insight and Potential Clinical Use.LOX-1(凝集素样氧化型低密度脂蛋白受体 1)作为心血管风险预测因子的作用:机制见解和潜在临床应用。
Arterioscler Thromb Vasc Biol. 2021 Jan;41(1):153-166. doi: 10.1161/ATVBAHA.120.315421. Epub 2020 Nov 12.
5
Soluble LOX-1: A Novel Biomarker in Patients With Coronary Artery Disease, Stroke, and Acute Aortic Dissection?可溶性凝集素样氧化低密度脂蛋白受体-1:冠心病、中风和急性主动脉夹层患者的新型生物标志物?
J Am Heart Assoc. 2020 Jan 7;9(1):e013803. doi: 10.1161/JAHA.119.013803. Epub 2020 Jan 4.
6
Membrane Cholesterol Modulates LOX-1 Shedding in Endothelial Cells.膜胆固醇调节内皮细胞中凝集素样氧化低密度脂蛋白受体1的脱落
PLoS One. 2015 Oct 23;10(10):e0141270. doi: 10.1371/journal.pone.0141270. eCollection 2015.
7
Clinical and Preclinical Use of LOX-1-Specific Antibodies in Diagnostics and Therapeutics.LOX-1特异性抗体在诊断和治疗中的临床及临床前应用
J Cardiovasc Transl Res. 2015 Nov;8(8):458-65. doi: 10.1007/s12265-015-9655-z. Epub 2015 Sep 18.
8
Molecular mechanism of statin-mediated LOX-1 inhibition.他汀类药物介导的凝集素样氧化低密度脂蛋白受体-1(LOX-1)抑制的分子机制。
Cell Cycle. 2015;14(10):1583-95. doi: 10.1080/15384101.2015.1026486.
9
Role of advanced glycation end products in cellular signaling.晚期糖基化终末产物在细胞信号传导中的作用。
Redox Biol. 2014 Jan 9;2:411-29. doi: 10.1016/j.redox.2013.12.016. eCollection 2014.